Keyword: Medicare

After a CMS rule change in August, UnitedHealthcare is introducing step therapy in Medicare Advantage plans to favor biosimilars over certain brands.

Federal officials unveiled changes to Medicare Part B this week that could result in lower sales for Amgen and Regeneron.

PhRMA called new donut-hole drug discounts a "massive bailout" for payers, but the insurance lobby says pharma's arguments are "ridiculous."

Pharma suffered a blow in the Senate's budget deal, but how much will drugmakers really lose? Not a lot, on average, but some will take a bigger hit.

Pharma stands to prevail again in Washington, D.C., if a new Part D rule proposal from the Centers for Medicare & Medicaid Services makes its way into law.

A new study in JAMA has put the focus back on the price of Mallinckrodt's controversial med, H.P. Acthar gel.

Gilead hit with revived lawsuit claiming it sourced a key HIV drug ingredient from an unapproved Chinese manufacturer.

One prominent pharma CEO figures overhauling healthcare won't take a few weeks of work. Think years—even decades.

If a proposed change in the way Medicare pays for injected drugs that doctors give at their offices goes forward, some companies will be hit harder than others. And according to a new report, one drugmaker in particular is at risk: Regeneron. And that is because of its strength in the marketplace, Eylea.

Amid a Republican push to repeal and replace Obamacare, Pfizer CEO Ian Read took his drug pricing message to the Washington press corps.